中草药

中药防治脏器纤维化的研究进展

PDF下载

中草药 | 中药防治器官纤维化研究 2026,57(18): 7073-7085

收起

中草药 |中药防治器官纤维化研究 2026 , 57 (18) : 7073 -7085

中药防治脏器纤维化的研究进展

全屏

哈庆旭¹, 程明涵¹, 高建¹

作者信息

通讯作者:

高建

作者简介:

哈庆旭: 哈庆旭，硕士，研究方向为肺纤维化分子机制。E-mail:17318590728@163.com

Research progress on traditional Chinese medicine in prevention and treatment of organ fibrosis

HA Qingxu¹, CHENG Minghan¹, GAO Jian¹

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.18.001

文章导航

摘要

收起

脏器纤维化是多种慢性疾病进展至终末期的重要病理基础，其发生发展与慢性损伤、炎症免疫反应、成纤维细胞活化、细胞外基质（extracellular matrix，ECM）沉积及组织结构重塑等密切相关。目前，临床抗纤维化治疗仍存在疗效有限、晚期病变难以逆转等问题。中药具有多成分、多靶点等特点，在脏器纤维化防治中显示一定研究潜力。通过综述近年来中药防治脏器纤维化的研究进展，介绍纤维化发生发展的病理基础及中医“本虚标实”“久病入络”等理论认识，重点总结中药通过调控转化生长因子-β/Smad、核因子-κB、核因子E2相关因子/血红素加氧酶-1等信号通路，影响炎症反应、氧化应激、ECM代谢、细胞表型转化、自噬、铁死亡、细胞衰老及代谢重编程等过程发挥抗纤维化作用的相关机制，并对肝、肺、肾及心肌纤维化领域中代表性中药复方、中成药及活性成分的研究现状进行归纳。当前，中药抗纤维化研究仍存在作用机制不够明确、药效物质基础不清及长期疗效和安全性证据不足等问题。今后应结合多组学、单细胞测序等技术，进一步明确主要活性成分和作用靶点，并通过规范的临床试验评价其长期疗效与安全性，为中药防治脏器纤维化的临床应用提供依据。

关键词

中药 / 脏器纤维化 / 纤维化机制 / 信号通路 / 多靶点调控

Abstract

收起

Organ fibrosis is an important pathological basis for the progression of many chronic diseases to the end stage. Its development is closely associated with chronic injury, inflammatory and immune responses, fibroblast activation, extracellular matrix (ECM) deposition, and tissue structural remodeling. Current antifibrotic therapies have limited efficacy, and advanced fibrosis remains difficult to reverse. Traditional Chinese medicine (TCM), characterized by multiple components and multiple targets, has been investigated as a potential approach for the prevention and treatment of organ fibrosis. This review summarizes recent progress in the use of TCM for organ fibrosis, including the pathological basis of fibrosis and TCM concepts of “root deficiency with branch excess” and “chronic illness entering the collaterals.” Particular attention is given to mechanisms involving transforming growth factor-β/Smad, nuclear factor-κB, and nuclear factor E2 related factor 2/heme oxygenase-1 signaling and to processes including inflammation, oxidative stress, ECM metabolism, cell phenotypic transition, autophagy, ferroptosis, cellular senescence, and metabolic reprogramming. The current research on representative TCM formulas, proprietary Chinese medicines, and active compounds for liver, pulmonary, renal, and myocardial fibrosis is also reviewed. Current studies on TCM antifibrosis still have limitations such as insufficiently clarified mechanisms of action, unclear pharmacodynamic material basis, and inadequate evidence of long-term efficacy and safety. Future studies should identify the major active components and molecular targets of TCM by integrating multi-omics, single-cell sequencing and other technologies, and evaluate long-term efficacy and safety in well-designed clinical trials, so as to provide evidence for the clinical application of TCM in the prevention and treatment of organ fibrosis.

Key words

traditional Chinese medicine / organ fibrosis / mechanisms of fibrosis / signaling pathways / multi-target regulation

引用本文

哈庆旭, 程明涵, 高建. 中药防治脏器纤维化的研究进展. 中草药, 2026 , 57 (18) : 7073 -7085 . DOI: 10.7501/j.issn.0253-2670.2026.18.001

HA Qingxu, CHENG Minghan, GAO Jian. Research progress on traditional Chinese medicine in prevention and treatment of organ fibrosis[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (18) : 7073 -7085 . DOI: 10.7501/j.issn.0253-2670.2026.18.001

基金

收起

国家自然科学基金资助项目 (81973637); 国家自然科学基金资助项目 (82373933)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Henderson N C, Rieder F, Wynn T A. Fibrosis:From mechanisms to medicines[J]. Nature, 2020, 587(7835):555-566.
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):151-166.
Distler J H W, Györfi A H, Ramanujam M, et al. Shared and distinct mechanisms of fibrosis[J]. Nat Rev Rheumatol, 2019, 15(12):705-730.
Liu B C, Tang T T, Lv L L, et al. Renal tubule injury:A driving force toward chronic kidney disease[J]. Kidney Int, 2018, 93(3):568-579.
Frangogiannis N G. Cardiac fibrosis:Cell biological mechanisms, molecular pathways and therapeutic opportunities[J]. Mol Aspects Med, 2019, 65:70-99.
World Health Organization. Guidelines for the prevention,diagnosis, care and treatment for people with chronic hepatitis B infection[M]. Geneva:World Health Organization, 2024.
European Association for the Study of the Liver(EASL),European Association for the Study of Diabetes(EASD),European Association for the Study of Obesity(EASO).EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. J Hepatol, 2024, 81(3):492-542.
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults:An official ATS/ERS/JRS/ALAT clinical practice guideline[J]. Am J Respir Crit Care Med, 2022,205(9):e18-e47.
King T E Jr, Bradford W Z, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22):2083-2092.
Richeldi L, du Bois R M, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22):2071-2082.
Stevens P E, Ahmed S B, Carrero J J, et al. KDIGO 2024clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int,2024, 105(4):S117-S314.
Ong C H, Tham C L, Harith H H, et al. TGF-β-induced fibrosis:A review on the underlying mechanism and potential therapeutic strategies[J]. Eur J Pharmacol, 2021,911:174510.
Frangogiannis N. Transforming growth factor-β in tissue fibrosis[J]. J Exp Med, 2020, 217(3):e20190103.
Wynn T, Barron L. Macrophages:Master regulators of inflammation and fibrosis[J]. Semin Liver Dis, 2010,30(3):245-257.
He F, Ru X L, Wen T. Nrf2, a transcription factor for stress response and beyond[J]. Int J Mol Sci, 2020, 21(13):4777.
Hao W L, Li M H, Cai Q M, et al. Roles of Nrf2 in fibrotic diseases:From mechanisms to therapeutic approaches[J]. Front Physiol, 2022, 13:889792.
Pakshir P, Hinz B. The big five in fibrosis:Macrophages,myofibroblasts, matrix, mechanics, and miscommunication[J]. Matrix Biol, 2018, 68/69:81-93.
Lai W J, Wang B, Huang R S, et al. Ferroptosis in organ fibrosis:From mechanisms to therapeutic medicines[J]. J Transl Intern Med, 2024, 12(1):22-34.
Schafer M J, White T A, Iijima K, et al. Cellular senescence mediates fibrotic pulmonary disease[J]. Nat Commun, 2017, 8:14532.
Zhu X Y, Jiang L L, Long M T, et al. Metabolic reprogramming and renal fibrosis[J]. Front Med, 2021, 8:746920.
Di X P, Gao X S, Peng L, et al. Cellular mechanotransduction in health and diseases:From molecular mechanism to therapeutic targets[J]. Signal Transduct Target Ther, 2023, 8(1):282.
Yeh C F, Chou C, Yang K C. Mechanotransduction in fibrosis:Mechanisms and treatment targets[J]. Curr Top Membr, 2021, 87:279-314.
郑钰,刘创,庞立健,等.基于络病理论防治多器官纤维化异病同治刍议[J]. 时珍国医国药, 2018, 29(5):1175-1177.
Li H. Advances in anti hepatic fibrotic therapy with traditional Chinese medicine herbal formula[J]. J Ethnopharmacol, 2020, 251:112442.
李世粉,杨若轩,孙健,等.黄芪有效成分防治器官纤维化的研究进展[J]. 药学学报, 2023, 58(8):2168-2179.
Gong F Y, Qu R M, Li Y C, et al. Astragalus mongholicus:A review of its anti-fibrosis properties[J]. Front Pharmacol, 2022, 13:976561.
Wang Q, Xu J C, Li M M, et al. Nrf2 knockout attenuates the astragaloside IV therapeutic effect on kidney fibrosis from liver cancer by regulating pSmad3C/3L pathways[J]. Naunyn Schmiedebergs Arch Pharmacol, 2024, 397(3):1687-1700.
Wang L, Chi Y F, Yuan Z T, et al. Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro[J]. Exp Biol Med,2014, 239(10):1310-1324.
冯科冉,李伟霞,王晓艳,等.丹参化学成分、药理作用及其质量标志物(Q-Marker)的预测分析[J]. 中草药, 2022, 53(2):609-618.
Jiang N, Zhang J, Ping J, et al. Salvianolic acid B inhibits autophagy and activation of hepatic stellate cells induced by TGF-β1 by downregulating the MAPK pathway[J]. Front Pharmacol, 2022, 13:938856.
Liu Y W, Huang Y T. Inhibitory effect of tanshinone IIA on rat hepatic stellate cells[J]. PLoS One, 2014, 9(7):e103229.
Xu L J, Zhang Y R, Ji N B, et al. Tanshinone IIA regulates the TGF-β1/Smad signaling pathway to ameliorate nonalcoholic steatohepatitis-related fibrosis[J]. Exp Ther Med, 2022, 24(1):486.
Sies H, Jones D P. Reactive oxygen species(ROS)as pleiotropic physiological signalling agents[J]. Nat Rev Mol Cell Biol, 2020, 21(7):363-383.
Liu R M, Desai L P. Reciprocal regulation of TGF-β and reactive oxygen species:A perverse cycle for fibrosis[J]. Redox Biol, 2015, 6:565-577.
Wynn T A, Vannella K M. Macrophages in tissue repair,regeneration, and fibrosis[J]. Immunity, 2016, 44(3):450-462.
Hoque M M, Gbadegoye J O, Hassan F O, et al. Cardiac fibrogenesis:An immuno-metabolic perspective[J]. Front Physiol, 2024, 15:1336551.
Koyama Y, Brenner D A. Liver inflammation and fibrosis[J]. J Clin Investig, 2017, 127(1):55-64.
Guo S, Zhang Q, Guo Y J, et al. The role and therapeutic targeting of the CCL2/CCR2 signaling axis in inflammatory and fibrotic diseases[J]. Front Immunol,2025, 15:1497026.
Paik S, Kim J K, Silwal P, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation[J]. Cell Mol Immunol, 2021, 18(5):1141-1160.
Song Z H, Gong Q, Guo J W. Pyroptosis:Mechanisms and links with fibrosis[J]. Cells, 2021, 10(12):3509.
Xu Y, Cao L X, Zou W L, et al. Panax notoginseng saponins inhibits NLRP3 inflammasome-mediated pyroptosis by downregulating lncRNA-ANRIL in cardiorenal syndrome type 4[J]. Chin Med, 2023, 18(1):50.
Li S, Lin Q S, Shao X H, et al. NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation[J]. Exp Cell Res, 2019, 383(1):111488.
Ma L B, Li H, Zhang S C, et al. Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2[J]. Int Urol Nephrol, 2018,50(2):373-382.
Hinz B, Lagares D. Evasion of apoptosis by myofibroblasts:A hallmark of fibrotic diseases[J]. Nat Rev Rheumatol, 2020, 16(1):11-31.
Tang D L, Chen X, Kang R, et al. Ferroptosis:Molecular mechanisms and health implications[J]. Cell Res, 2021,31(2):107-125.
Hamanaka R B, Mutlu G M. Metabolic requirements of pulmonary fibrosis:Role of fibroblast metabolism[J]. FEBS J, 2021, 288(22):6331-6352.
Kang H M, Ahn S H, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development[J]. Nat Med, 2015, 21(1):37-46.
Lehmann M, Korfei M, Mutze K, et al. Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo[J]. Eur Respir J, 2017,50(2):1602367.
Pakshir P, Noskovicova N, Lodyga M, et al. The myofibroblast at a glance[J]. J Cell Sci, 2020, 133(13):jcs227900.
Meng X M, Nikolic-Paterson D J, Lan H Y. TGF-β:The master regulator of fibrosis[J]. Nat Rev Nephrol, 2016,12(6):325-338.
MassaguéJ, Sheppard D. TGF-β signaling in health and disease[J]. Cell, 2023, 186(19):4007-4037.
Nakao A, Afrakhte M, Morén A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling[J]. Nature, 1997, 389(6651):631-635.
Jones D L, Hallström G F, Jiang X, et al.Mechanoepigenetic regulation of extracellular matrix homeostasis via YAP and TAZ[J]. Proc Natl Acad Sci USA, 2023, 120(22):e2211947120.
Liu F, Lagares D, Choi K M, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis[J]. Am J Physiol Lung Cell Mol Physiol, 2015,308(4):L344-L357.
Liu F, Mih J D, Shea B S, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression[J]. J Cell Biol, 2010, 190(4):693-706.
Mascharak S, L Guo J, Griffin M, et al. Modelling and targeting mechanical forces in organ fibrosis[J]. Nat Rev Bioeng, 2024, 2(4):305-323.
Laronha H, Caldeira J. Structure and function of human matrix metalloproteinases[J]. Cells, 2020, 9(5):1076.
Brew K, Nagase H. The tissue inhibitors of metalloproteinases(TIMPs):An ancient family with structural and functional diversity[J]. Biochim Biophys Acta BBA Mol Cell Res, 2010, 1803(1):55-71.
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease[J]. Nat Rev Mol Cell Biol, 2014, 15(12):786-801.
木林洁,董飞侠,姜程曦,等.肾病I号方醋酸乙酯提取物对单侧输尿管梗阻大鼠肾间质纤维化的影响[J]. 中草药, 2017, 48(7):1380-1385.
陶诗怡,于林童,李军,等.中医药干预扩张型心肌病作用机制研究进展[J]. 中草药, 2024, 55(23):8222-8234.
Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis:Pathophysiological mechanisms and therapy[J]. JHEP Rep, 2021, 3(4):100316.
Paulus W J, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction:Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol, 2013, 62(4):263-271.
Rysz J, Franczyk B,Ławiński J, et al. The impact of CKD on uremic toxins and gut microbiota[J]. Toxins, 2021,13(4):252.
Hancock L A, Hennessy C E, Solomon G M, et al. Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice[J]. Nat Commun, 2018, 9:5363.
Chen J M, Hu Y H, Chen L, et al. The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases[J]. Biomed Pharmacother, 2019, 114:108846.
Liu C H, Hu Y Y, Xu L M, et al. Effect of Fuzheng Huayu formula and its actions against liver fibrosis[J]. Chin Med,2009, 4:12.
Rong G H, Chen Y P, Yu Z J, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir:A multicenter,randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225(6):1091-1099.
Dong S, Cai F F, Chen Q L, et al. Chinese herbal formula Fuzheng Huayu alleviates CCl4-induced liver fibrosis in rats:A transcriptomic and proteomic analysis[J]. Acta Pharmacol Sin, 2018, 39(6):930-941.
Wu M, Zhou Y, Qin S L, et al. Fuzheng Huayu Capsule attenuates hepatic fibrosis by inhibiting activation of hepatic stellate cells[J]. Evid Based Complementary Altern Med, 2020, 2020(1):3468791.
Saidi A, Kasabova M, Vanderlynden L, et al. Curcumin inhibits the TGF-β1-dependent differentiation of lung fibroblasts via PPARγ-driven upregulation of cathepsins B and L[J]. Sci Rep, 2019, 9:491.
Lu Z Y, Liu S W, Xie Y S, et al. Inhibition of the tubular epithelial-to-mesenchymal transition in vivo and in vitro by the Uremic Clearance Granule(尿毒清颗粒)[J]. Chin J Integr Med, 2013, 19(12):918-926.
Wei Y C, Wu Y, Feng K, et al. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway[J]. J Ethnopharmacol, 2020, 249:112404.
Jin Y G, Yuan Y, Wu Q Q, et al. Puerarin protects against cardiac fibrosis associated with the inhibition of TGF-β1/Smad2-mediated endothelial-to-mesenchymal transition[J]. PPAR Res, 2017, 2017:2647129.
Dai H L, Jia G Z, Lu M L, et al. Astragaloside IV inhibits isoprenaline-induced cardiac fibrosis by targeting the reactive oxygen species/mitogen-activated protein kinase signaling axis[J]. Mol Med Rep, 2017, 15(4):1765-1770.
Hernández-Gea V, Ghiassi-Nejad Z, Rozenfeld R, et al.Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues[J]. Gastroenterology, 2012, 142(4):938-946.
Jin L N, Yu B F, Liu G J, et al. Mitophagy induced by UMI-77 preserves mitochondrial fitness in renal tubular epithelial cells and alleviates renal fibrosis[J]. FASEB J,2022, 36(6):e22342.
Pan T L, Wang P W. Explore the molecular mechanism of apoptosis induced by tanshinone IIA on activated rat hepatic stellate cells[J]. Evid Based Complement Alternat Med, 2012, 2012:734987.
Liu Y, Tang A M, Liu M, et al. Tuberostemonine may enhance the function of the SLC7A11/glutamate antiporter to restrain the ferroptosis to alleviate pulmonary fibrosis[J]. J Ethnopharmacol, 2024, 318:116983.
Zhai X R, Zhu J Y, Li J, et al. Fraxetin alleviates BLMinduced idiopathic pulmonary fibrosis by inhibiting NCOA4-mediated epithelial cell ferroptosis[J]. Inflamm Res, 2023, 72(10/11):1999-2012.
Xing X R, Chen S, Li L, et al. The active components of fuzheng Huayu formula and their potential mechanism of action in inhibiting the hepatic stellate cells viability-a network pharmacology and transcriptomics approach[J]. Front Pharmacol, 2018, 9:525.
刘昌孝,陈士林,肖小河,等.中药质量标志物(QMarker):中药产品质量控制的新概念[J]. 中草药,2016, 47(9):1443-1457.
Mederacke I, Hsu C C, Troeger J S, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology[J]. Nat Commun, 2013, 4:2823.
Liu P, Hu Y Y, Liu C, et al. Multicenter clinical study on Fuzhenghuayu Capsule against liver fibrosis due to chronic hepatitis B[J]. World J Gastroenterol, 2005,11(19):2892-2899.
Gui H L, Zhao C Q, Wang Y, et al. Histological outcome of fuzheng Huayu plus entecavir combination therapy in chronic hepatitis B patients with significant liver fibrosis[J]. J Clin Transl Hepatol, 2020, 8(3):1-8.
Ji D, Chen Y, Bi J F, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol,2022, 77(6):1515-1524.
Zhang A J, Han K K, Chen F F, et al. Jinbei oral liquid for idiopathic pulmonary fibrosis:A randomized placebocontrolled trial[J]. Sci Rep, 2025, 15:3007.
Zhou M, Zhang H L, Li F L, et al. Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF:A randomized controlled trial[J]. Respirology, 2021, 26(4):360-369.
Li J S, Zhang H L, Guo W, et al. Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis:An exploratory randomized controlled trial[J]. J Integr Med,2023, 21(6):543-549.
Xing X Y, Qiang W J, Bao J L, et al. Jinbei Oral Liquid ameliorates bleomycin-induced idiopathic pulmonary fibrosis in rats via reversion of Th1/Th2 shift[J]. Chin Herb Med, 2020, 12(3):273-280.
宋剑,李彦华,杨向东,等.百令胶囊联合贝那普利对早期糖尿病肾病患者尿白蛋白排泄率及C反应蛋白的影响[J]. 中国中西医结合杂志, 2009, 29(9):791-793.
Duan S W, Ding Z R, Liu C, et al. Icariin suppresses nephrotic syndrome by inhibiting pyroptosis and epithelial-to-mesenchymal transition[J]. PLoS One, 2024,19(7):e0298353.

2026年第57卷第18期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.18.001

接收时间：2026-05-01
首发时间：2026-10-29

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-05-01

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.18.001

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT